Clinical trial · Interventional
Influenza Vaccine Post Allogeneic Transplant
MT2010-08R Influenza Vaccine Specific Immune Responses After Allogeneic Hematopoietic Cell Transplantation: Are One or Two Vaccine Doses Needed?
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Lack of patients and no longer influenza vaccine season.
Summary
Brief summary (as posted)
Study Design: This is a randomized, single center study to evaluate immune responses to the seasonal influenza vaccine in allogeneic hematopoietic stem cell transplant (HSCT) recipients who receive one vaccine or two vaccine doses one month apart. In addition, a cohort of healthy adult volunteers will be recruited as controls to confirm immune response to a single influenza vaccine.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Malignancy | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
| Hematopoietic Stem Cell Transplant | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Influenza vaccine | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Participants Receiving 1 Dose of Vaccine
- description
- Control group participants (healthy volunteers): * Age 18 to 50 years * No history of previous allergic reaction to influenza vaccine, known egg allergy or Guillan-Barre Syndrome * No flu vaccine in previous 4 months and/or HSCT recipients who are greater than 60 days post transplant.
- interventionNames
- Biological: Influenza vaccine
- type
- ACTIVE_COMPARATOR
- label
- Participants Receiving 2 Doses of Vaccine
- description
- Hematopoietic stem cell transplant (HSCT) recipients who are greater than 60 days post transplant.
- interventionNames
- Biological: Influenza vaccine
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 6 Months
Show eligibility criteria text
Inclusion Criteria: * Patient Population * HSCT recipients who are greater than 60 days post transplant. * Age 6 months and older who are greater than 60 days post post allogeneic hematopoietic cell transplant * Show neutrophil recovery, platelet count \> 50,000/mm3 (may be transfused), no known disease relapse * No history of previous allergic reaction to influenza vaccine, known egg allergy or Guillan-Barre Syndrome * No flu vaccine in previous 4 months, no Campath in previous 6 months, no intravenous immune globulin (IVIG) in previous 3 months * Controls: * Age 18 to 50 years * No history of previous allergic reaction to influenza vaccine, known egg allergy or Guillan-Barre Syndrome * No flu vaccine in previous 4 months
References
Publications (0)
Data not yet available